Novel EZH2 mutation in a patient with secondary B-cell acute lymphocytic leukemia after deletion 5q myelodysplastic syndrome treated with lenalidomide: A case report

RATIONALE: The gene deletion (5)(q22q35) is reported in 10–20% of myelodysplastic syndrome (MDS) cases and is associated with response to lenalidomide and favorable prognosis. The authors report here a clinical case of MDS transformation to B-cell acute lymphocytic leukemia (B-ALL) with an associate...

Descripción completa

Detalles Bibliográficos
Autores principales: Burgos, Sebastian, Montalban-Bravo, Guillermo, Fuente, Lucia, Jabbour, Elias J., Kanagal-Shamanna, Rashmi, Soltysiak, Kelly A., Garcia-Manero, Guillermo, Mela-Osorio, Maria J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6344201/
https://www.ncbi.nlm.nih.gov/pubmed/30608448
http://dx.doi.org/10.1097/MD.0000000000014011

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6344201/
https://www.ncbi.nlm.nih.gov/pubmed/30608448
http://dx.doi.org/10.1097/MD.0000000000014011

Ejemplares similares